PetVivo (PETV) Q3 2025 earnings summary

Executive summary

• Achieved a 191% sequential revenue increase to $583,000 in Q3, driven by expanded distribution for Spryng with OsteoCushion technology.

• Over 800 veterinary clinics across all 50 states have used Spryng since its 2021 launch.

• Focus shifted toward the larger companion animal market, with realignment and expansion of the sales force.

• Leadership strengthened with the appointment of Mike Eldred as Executive Director and Commercial and Operations Advisor.

• PetVivo Holdings operates as a single segment from its headquarters in Edina, Minnesota, manufacturing in ISO-certified facilities.

Financial highlights

• Q3 revenues rose 191% sequentially to $583,000, but were nearly flat year-over-year at $583,313 compared to $595,891.

• Gross profit for Q3 was $522,000, maintaining a high gross margin of 89.5%.

• Operating expenses for the nine months ended December 31, 2024, decreased by $2 million (23%) year-over-year.

• Net loss for the nine months was $5,979,594 ($0.30 per share), improved from $8,304,578 ($0.64 per share) in the prior year.

• Cash and cash equivalents at quarter-end were $28,891, rising to $418,000 after a $1.1 million capital raise.

Outlook and guidance

• Continued focus on expanding both equine and small animal markets.

• Ongoing accumulation of clinical data and pursuit of new clinical trials to support product adoption.

• Expectation to engage large corporate veterinary clinic groups in upcoming quarters.

• Management expects to continue raising capital through securities sales to fund commercialization and operations.

• The company anticipates ongoing losses and will require additional financing to support business expansion and commercialization of Spryng™.